Iliescu Cezar, Grines Cindy L, Herrmann Joerg, Yang Eric H, Cilingiroglu Mehmet, Charitakis Konstantinos, Hakeem Abdul, Toutouzas Konstantinos, Leesar Massoud A, Marmagkiolis Konstantinos
University of Texas, MD Anderson Cancer Center, Houston, Texas.
Detroit Medical Center, Cardiovascular Institute, Detroit, Michigan.
Catheter Cardiovasc Interv. 2016 Apr;87(5):895-9. doi: 10.1002/ccd.26375. Epub 2015 Dec 23.
In the United States alone, there are currently approximately 14.5 million cancer survivors, and this number is expected to increase to 20 million by 2020. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes (ACS), stroke, critical limb ischemia, arrhythmias, and heart failure, independently from the direct myocardial or pericardial damage from the malignancy itself. Consequently, the need for invasive evaluation and management in the cardiac catheterization laboratory (CCL) for such patients has been increasing. In recognition of the need for a document on special considerations for cancer patients in the CCL, the Society for Cardiovascular Angiography and Interventions (SCAI) commissioned a consensus group to provide recommendations based on the published medical literature and on the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients.
仅在美国，目前就有约1450万癌症幸存者，预计到2020年这一数字将增至2000万。癌症治疗可对脉管系统造成严重损伤，导致心绞痛、急性冠脉综合征（ACS）、中风、严重肢体缺血、心律失常及心力衰竭，这与恶性肿瘤本身直接造成的心肌或心包损伤无关。因此，此类患者在心脏导管实验室（CCL）进行侵入性评估和治疗的需求不断增加。认识到需要一份关于CCL中癌症患者特殊考量的文件，心血管造影和介入学会（SCAI）委托一个共识小组根据已发表的医学文献以及在癌症患者心脏导管插入术方面积累了经验的操作人员的专业知识提供建议。
